Atazanavir

Active ingredient description

Atazanavir is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
J05AE08
Atazanavir
J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE08

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
REYATAZ Hard capsules
Summary of Product Characteristics (SPC)

Medicines

Atazanavir is the active ingredient of these drugs:

Drug
Countries
ANCEF

Ecuador

ANOVAVIR

South Africa

ATAHIV

South Africa

ATAZOR

South Africa

CONVIROX

Ecuador

REYATAZ

Australia Austria Brazil Canada Cyprus

SYNTHITAZ

South Africa

VIRATAN

South Africa

ZOROVIR

South Africa

Atazanavir is also found within below combination drugs:

EVOTAZ , RIATEM , RITOATAZ

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₃₈H₅₂N₆O₇
Molecular mass: 704.856 g/mol

External identifiers

CAS Substance: 198904-31-3
DrugBank Drug: DB01072
KEGG Drug: D07471
PubChem Compound: 148192
RxNorm Ingredient: 343047
SNOMED-CT Concept: 413592000
Atazanavir (substance)
UNII Identifier: QZU4H47A3S
ATAZANAVIR
 
Next: Usage >